Opus Genetics reports positive OPGx-BEST1 Phase 1/2 data
Opus Genetics reported positive safety and proof-of-concept results from low-dose Cohort 1 of OPGx-BEST1, with functional and structural gains in treated patients.
Key Highlights:Original SEC Filing: Opus Genetics, Inc. [ IRD ] - 8-K - Sep. 09, 2026This is an AI-powered summary. It may contain inaccu…